ReviewJournal of cellular biochemistry2008
Targeting vasculature in urologic tumors: mechanistic and therapeutic significance.
Review in Journal of cellular biochemistry, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Profiling Prostate Cancer Therapeutic Resistance.International journal of molecular sciences · 2018Review
- Therapeutic challenges in renal cell carcinoma.American journal of clinical and experimental urology · 2015Review
- The role of the RhoA/Rho kinase pathway in angiogenesis and its potential value in prostate cancer (Review).Oncology letters · 2014Article
- Therapeutic value of quinazoline-based compounds in prostate cancer.Anticancer research · 2013Review
- Tivozanib in the treatment of renal cell carcinoma.Biologics : targets & therapy · 2013Article
- Efficient (18)F-labeling of large 37-amino-acid pHLIP peptide analogues and their biological evaluation.Bioconjugate chemistry · 2012Article
- The role of vitamin D in cancer prevention and treatment.Rheumatic diseases clinics of North America · 2012Article
- Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma.Drugs · 2011Review
- Targeting of α(v)-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer.Neoplasia (New York, N.Y.) · 2011Article
- The role of vitamin D in cancer prevention and treatment.Endocrinology and metabolism clinics of North America · 2010Review
- Beta1 integrin cytoplasmic variants differentially regulate expression of the antiangiogenic extracellular matrix protein thrombospondin 1.Cancer research · 2009Article
- Extratumoral macrophages promote tumor and vascular growth in an orthotopic rat prostate tumor model.Neoplasia (New York, N.Y.) · 2009Article
- Molecular targets and targeted therapies in bladder cancer management.World journal of urology · 2009Review
- Integrins in prostate cancer progression.Endocrine-related cancer · 2008Review
- Molecular aspects of renal cell carcinoma: a review.American journal of cancer researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Recent advances toward understanding the molecular mechanisms regulating cancer initiation and progression provide new insights into the therapeutic value of targeting tumor vascularity by interfering with angiogenic signaling pathways. The functional contribution of key angiogenic factors toward increased vascularity characterizing metastatic tumors and their therapeutic exploitation is considered in three major urologic malignancies, renal, bladder, and prostate cancer. With the realization that the success of the therapeutic efficacy of the various anti-angiogenic approaches for the treatment of urologic tumors has yet to be proven clinically, the challenge remains to select critical angiogenesis pathways that can be targeted for an individual tumor. Here we discuss the major mechanisms that support formation of vasculature in renal, bladder, and prostate tumors and the current results of targeting of specific molecules/regulators for therapeutic intervention against metastastic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.